Search Result

Results for "

FKBPs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (11) Apoptosis (8) AUTACs (2) Autophagy (22) Bacterial (14) BCL6 (1) Biochemical Assay Reagents (2) c-Myc (1) Calcium Channel (2) CDK (1) Drug Intermediate (1) Drug Metabolite (2) E3 Ligase Ligand-Linker Conjugates (2) EGFR (1) Endogenous Metabolite (9) Epigenetic Reader Domain (5) Estrogen Receptor/ERR (3) FKBP (79) Fungal (6) Glucocorticoid Receptor (1) HSP (2) Isotope-Labeled Compounds (7) Ligands for E3 Ligase (2) Ligands for Target Protein for PROTAC (9) mTOR (13) Parasite (1) Phosphatase (5) PhosTACs (1) Progesterone Receptor (3) PROTACs (20) Proteasome (2) Proteasome Cap Targeting Chimeras (1) Reference Standards (7) Small Interfering RNA (siRNA) (36) Target Protein Ligand-Linker Conjugates (3)
By Research Areas:	Cancer (77) Endocrinology (3) Infection (9) Inflammation/Immunology (10) Metabolic Disease (7) Neurological Disease (12)
Click Chemistry:	Alkynes (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (11) Mouse Pre-designed siRNA Sets (11) Human Pre-designed siRNA Sets (14) siRNAs (36)

134

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10218

Everolimus 110+ Cited Publications RAD001; SDZ-RAD	mTOR FKBP Autophagy Apoptosis Bacterial	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective, orally active, blood-brain barrier-permeable mTOR1 inhibitor. Everolimus binds to *FKBP-12* to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

HY-13992

AP20187 45+ Cited Publications B/B Homodimerizer	FKBP	Metabolic Disease
AP20187 (B/B Homodimerizer) is a cell-permeable ligand used to dimerize FK506-binding protein (FKBP) fusion proteins and initiate biological signaling cascades and gene expression or disrupt protein-protein interactions.

HY-112210

Shield-1 5+ Cited Publications Shld1	FKBP	Others
Shield-1 (Shld1) is a specific, cell-permeant and high-affinity ligand of FK506-binding protein-12 (FKBP), and reverses the instability by binding to *mutated FKBP* (mtFKBP)*, allowing conditional expression of mtFKBP-fused proteins. Shield-1 can stabilize proteins tagged with a mutated FKBP*12-derived destabilization domain (DD) .

HY-16046

Rimiducid 50+ Cited Publications AP1903	FKBP Apoptosis	Cancer
Rimiducid (AP1903) is a dimerizer agent that acts by cross-linking the *FKBP* domains. Rimiducid (AP1903) dimerizes the Caspase 9 suicide switch and rapidly induces apoptosis.

HY-145514

dTAGV-1 TFA 5 Publications Verification	PROTACs FKBP	Cancer
dTAGV-1 TFA is a potent and selective degrader of FKBP12 ^F36V-tagged proteins PROTAC degrader. dTAGV-1 TFA can induce degradation of FKBP12 ^F36V-Nluc in vivo. (Pink: Target Protein Ligand (HY-114420); Black: Linker (HY-W012001); Blue: VHL Ligand (HY-112078); VHL Ligan+Linker (HY-173628A))

HY-145514C

dTAGV-1 hydrochloride 5 Publications Verification	FKBP PROTACs	Cancer
dTAGV-1 hydrochloride is a potent and selective degrader of FKBP12 ^F36V-tagged proteins PROTAC degrader. dTAGV-1 hydrochloride can induce degradation of FKBP12 ^F36V-Nluc in vivo. (Pink: Target Protein Ligand (HY-114420); Black: Linker (HY-W012001); Blue: VHL Ligand (HY-112078); VHL Ligan+Linker (HY-173628A)) .

HY-114872

SLF 1 Publications Verification	Ligands for Target Protein for PROTAC FKBP	Cancer
SLF is a synthetic ligand for FK506-binding protein (FKBP) with an affinity of 3.1 μM for *FKBP51* and an IC₅₀ of 2.6 μM for *FKBP12*. SLF can be used in the synthesis of PROTAC .

HY-114434

AP1867 4 Publications Verification	FKBP	Cancer
AP1867 is a synthetic FKBP12 ^F36V-directed ligand .

HY-147098

dTAG-47 1 Publications Verification	PROTACs FKBP	Cancer
dTAG-47 is a *FKBP12F36V* PROTAC degrader. dTAG-47 efficiently degrades *FKBP12F36V-MELK(sg3R)* in MELK ^⁻/⁻ MDA-MB-468-FKBP12F36V-MELK(sg3R) cells. dTAG-47 can be used for the research of basal-like breast cancers (BBC). (Pink: FKBP12F36V ligand (HY-114420), Blue: CRBN Ligand (HY-W087383), Black: Linker (HY-42773), E3 ligase ligand-linker conjugate (HY-175952)) .

HY-153806

RapaBlock ZZY05-092	FKBP	Cancer
RapaBlock is a potent, non-immunosuppressive and brain-impermeable *FKBP12* ligand .

HY-114421

FKBP12 PROTAC dTAG-13 5+ Cited Publications dTAG-13	PROTACs FKBP	Cancer
FKBP12 PROTAC dTAG-13 (dTAG-13), a PROTAC-based heterobifunctional degrader, is a selective degrader of FKBP12 ^F36V with expression of FKBP12F36V in-frame with a protein of interest. FKBP12 PROTAC dTAG-13 effectively engages FKBP12 ^F36V and CRBN, thereby selectively degrading FKBP12 ^F36V .

HY-161157

dTAG-13-NEG	PROTACs	Cancer
dTAG-13-NEG is a negative control of dTAG-13 (HY-114421). dTAG-13, a PROTAC-based heterobifunctional degrader, is a selective degrader of FKBP12 ^F36V with expression of FKBP12F36V in-frame with a protein of interest .

HY-145514A

dTAGV-1-NEG	PROTACs FKBP	Cancer
dTAGV-1-NEG is a diastereomer and as a heterobifunctional negative control of dTAGV-1. dTAGV-1 is an FKBP12 ^F36V-selective degrader .

HY-130835

FKBP12 PROTAC RC32 RC32	PROTACs FKBP	Cancer
FKBP12 PROTAC RC32 (RC32) is a potent *FKBP12* degrader based on PROTAC technology. FKBP12 PROTAC RC32 contains conjugation of Rapamycin (HY-10219) and a ligand for an Cereblon E3 ubiquitin ligase (Pomalidomide; HY-10984) .

HY-102079

SAFit1 1 Publications Verification	FKBP	Neurological Disease Metabolic Disease
SAFit1 is a FK506 binding protein 51 (FKBP51)-specific inhibitor with a K_i of 4±0.3 nM .

HY-103634

dFKBP-1 1 Publications Verification	PROTACs FKBP	Cancer
dFKBP-1 is a potent and PROTAC-based *FKBP12* degrader. dFKBP-1 incorporates the ligand SLF (HY-114872) of *FKBP12, the Thalidomide based Cereblon* ligand and a linker .

HY-123941

FKBP12 PROTAC dTAG-7 3 Publications Verification dTAG-7	PROTACs FKBP Epigenetic Reader Domain	Others
FKBP12 PROTAC dTAG-7 (dTAG-7) is a heterobifunctional PROTAC degrader. FKBP12 PROTAC dTAG-7 targets FKBP12 ^F36V and BET BRD4. FKBP12 PROTAC dTAG-7 enables rapid and selective degradation of target proteins, and is suitable for cellular and in vivo studies to analyze protein functions and validate targets . (Pink: target protein ligand (HY-114420); Black: linker (HY-128844); Blue: CRBN Ligand (HY-103597); CRBN Ligand+linker: (HY-W722323))

HY-163807

22-SLF	PROTACs FKBP	Cancer
22-SLF is a PROTAC degrader, that degrades FK506-binding protein 12 (FKBP12) with a DC₅₀ of 0.5 µM. 22-SLF interacts with C227 and C228 in FBXO22 to induce a ternary complex between FKBP12 and FBXO22, and degrades FKBP12 in a FBXO22-dependent manner. 22-SLF can be used for fundamental cancer research as a probe to study the FBXO22 degradation pathway. (Pink: FKBP12 ligand (HY-114872); Black: Linker (HY-163821); Blue: FBXO22 ligand (HY-163826)) .

HY-10218S

Everolimus-d4 RAD001-d₄; SDZ-RAD-d₄	mTOR FKBP Autophagy Apoptosis	Cancer
Everolimus-d₄ is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

HY-145514D

dTAGV-1 5 Publications Verification	PROTACs FKBP	Cancer
dTAGV-1 is a potent and selective degrader of FKBP12 ^F36V-tagged proteins PROTAC degrader. dTAGV-1 can induce degradation of FKBP12 ^F36V-Nluc in vivo. (Pink: Target Protein Ligand (HY-114420); Black: Linker (HY-W012001); Blue: VHL Ligand (HY-112078); VHL Ligan+Linker (HY-173628A)) .

HY-156820

HLDA-221	Epigenetic Reader Domain	Cancer
HLDA-221 is a non-covalent regulated induced proximity targeting chimeras (RIPTAC). The binding of HLDA-221 to BRD4-BD1 is significantly increased after pre-incubation with FKBP. HLDA-221 can be used in cancer research .

HY-10218R

Everolimus (Standard) RAD001 (Standard); SDZ-RAD (Standard)	Reference Standards mTOR FKBP Autophagy Apoptosis Bacterial	Cancer
Everolimus (Standard) is the analytical standard of Everolimus. This product is intended for research and analytical applications. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to *FKBP-12* to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

HY-129610

KB02-SLF	PROTACs FKBP	Cancer
KB02-SLF is a PROTAC-based nuclear *FKBP12* degrader (molecular glue). KB02-SLF promotes nuclear *FKBP12* degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. SLF binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-SLF .

HY-P4581

Suc-Ala-Leu-Pro-Phe-pNA Suc-ALPF-pNA	FKBP	Others
Suc-Ala-Leu-Pro-Phe-pNA (Suc-ALPF-pNA) is a synthetic polypeptide substrate that targets FK506-binding protein (FKBP). Suc-Ala-Leu-Pro-Phe-pNA can be used to determine peptidyl-prolyl cis-trans isomerase activity via the chymotrypsin-coupled assay. Suc-Ala-Leu-Pro-Phe-pNA serves as a substrate for human FK506-binding protein hFKBP-12 in the chymotrypsin-FKBP coupled PPIase assay. Suc-Ala-Leu-Pro-Phe-pNA is applicable for the detection and research of PPIase activity .

HY-135345

*PROTAC FKBP* Degrader-3** 1 Publications Verification	PROTACs FKBP	Cancer
PROTAC FKBP Degrader-3 is a PROTAC that comprises a *FKBP* ligand binding group, a linker and an von Hippel-Lindau binding group. PROTAC FKBP Degrader-3 is a potent *FKBP* degrader .

HY-107452

SLF-amido-C2-COOH PROTAC FKBP12-binding moiety 1	Ligands for Target Protein for PROTAC FKBP	Cancer
SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) is a synthetic ligand for *FKBP* (SLF). SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) can be used in the synthesis of PROTACs .

HY-114872A

SLF TFA 1 Publications Verification	Ligands for Target Protein for PROTAC FKBP	Cancer
SLF TFA is a synthetic ligand for FK506-binding protein (FKBP) with an affinity of 3.1 μM for *FKBP51* and an IC₅₀ of 2.6 μM for *FKBP12*. SLF TFA can be used in the synthesis of PROTAC .

HY-106345

ILS-920	FKBP Calcium Channel	Neurological Disease Inflammation/Immunology
ILS-920 is a nonimmunosuppressive Rapamycin analog with reduced immunosuppressive activity and potent neuroprotective activity. ILS-920 binds selectively to the immunophilin *FKBP52* and to the β1-subunit of L-type voltage-gated calcium channels (VGCC). ILS-920 shows 200-fold selectivity for *FKBP52* versus FKBP12 .

HY-129363

AP1867-3-(aminoethoxy)	Ligands for Target Protein for PROTAC FKBP	Cancer
AP1867-3-(aminoethoxy), the AP1867 (HY-114434) based moiety, is a synthetic ligand for FKBP. AP1867-3-(aminoethoxy) can be used in the synthesis of PROTAC FKBP12 F36V degrader .

HY-161794A

SP3N hydrochloride	FKBP	Cancer
SP3N hydrochloride is a specific degrader of the prolyl isomerase (FKBP12). The alkylamine of SP3N hydrochloride is metabolized to a reactive aldehyde (SP3CHO), which recruits the SCF ^FBXO22 ligase for *FKBP12* degradation. SP3N hydrochloride may be used in research for cancer .

HY-131344

mTOR inhibitor-8	mTOR Autophagy	Cancer
mTOR inhibitor-8 is an mTOR inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells .

HY-172265

FKBP12 PROTAC FM4	PROTACs FKBP	Cancer
FKBP12 PROTAC FM4 is a PROTAC degrader of *FKBP12, with a DC50* value of 0.09-0.22 nM. FKBP12 PROTAC FM4 inhibits global protein synthesis, induces apoptosis, and selectively reduces the viability of cervical cancer cells expressing MTH1-E6 and *FKBP12* ^F36V-tagged SARS1. FKBP12 PROTAC FM4 is applicable to research related to HPV-positive cervical cancer .

HY-159758

*EcDHFR/FKBP12 F36V binder-1*	Others	Neurological Disease Cancer
EcDHFR/FKBP12 F36V binder-1 (compound 1) is a bifunctional molecule that combines the Escherichia coli dihydrofolate reductase domain (EcDHFR) with the FKBP12 F36V domain .

HY-134184

AUTAC2	AUTACs Autophagy	Inflammation/Immunology Cancer
AUTAC2 is a *FKBP12*-targeting autophagy-mediated degrader (AUTAC). AUTAC2 contains an FBnG (p-Fluorobenzyl Guanine) and an SLF (c ligand of FKBP) moiety. SLF binds non-covalently to FKBP12 .

HY-176502

FKBP12 ligand-3	FKBP	Cancer
FKBP12 ligand-3 (compound dj) is a high-affinity ligand targeting *FKBP12. FKBP12 ligand-3 can be used to selectively enhance the binding of heterobifunctional molecules to BRD4, enriching the drug intracellularly through the "CellTrap" effect to form a ternary complex of FKBP12-ligand-BRD4. This ternary complex has inhibitory activity against BRD4, thereby inhibiting the expression of BRD4 target genes (such as MYC) and inducing tumor cell death. FKBP*12 ligand-3 can be used for selective cancer research based on differences in intracellular presenter protein levels .

HY-113646

Shield-2	FKBP	Others
Shield-2 is an efficient stabilizing ligand binding to the FKBP (F36V) protein with a dissociation constant of 29 nM. Shield-2 binds tightly to the *FKBP* mutants destabilizing domains and prevents degradation, thus providing small molecule regulation over intracellular protein levels .

HY-W017542

L-Pyrohomoglutamic acid	Drug Intermediate Biochemical Assay Reagents	Others
L-Pyrohomoglutamic acid is an amino acid building block. L-Pyrohomoglutamic acid can be used to synthesize ligands for FK506-binding proteins (FKBPs) and histone deacetylase (HDAC) inhibitors .

HY-158131

FKBP51-Hsp90-IN-2	FKBP HSP	Neurological Disease Cancer
FKBP51-Hsp90-IN-2 (Compound E08) is a selective *FKBP51-Hsp90* protein-protein interaction inhibitor with IC₅₀ values of 0.4 µM and 5 µM for *FKBP51* and *FKBP52, respectively. FKBP51-Hsp90-IN-2 also effectively stimulates cellular energy metabolism and neurite growth. FKBP*51-Hsp90-IN-2 can be used in research on neurodegenerative diseases and cancer .

HY-158130

FKBP51-Hsp90-IN-1	FKBP HSP	Neurological Disease Metabolic Disease Cancer
FKBP51-Hsp90-IN-1 (Compound D10) is a selective inhibitor of the *FKBP51-Hsp90* protein-protein interaction, with an IC₅₀ value of 0.1 μM against *FKBP51. FKBP*51-Hsp90-IN-1 can be used in the research of stress-related diseases, Alzheimer's disease, and metabolic disorders .

HY-176476

*BRD4/FKBP12 degrader-1*	Epigenetic Reader Domain FKBP	Cancer
BRD4/FKBP12 degrader-1(a1d) is a *BRD4/FKBP12* degrader with anti-cancer activity (BRD4 ligand: HY-78695, FKBP12 ligand: HY-176501, linker: HY-140212) .

HY-172266

FKBP12 Ligand-Linker Conjugate 2	Target Protein Ligand-Linker Conjugates	Others
FKBP12 Ligand-Linker Conjugate 2 is a conjugate of the FKBP12 target protein ligand and a linker, and it can be used for the synthesis of FKBP12 PROTAC FM4 (HY-172265) .

HY-W520748

MJC13	FKBP	Cancer
MJC13 is an *FKBP52*-targeted agent with anti-tumor activity that can be used in prostate cancer research .

HY-176501

FKBP12 ligand-2	FKBP	Cancer
FKBP12 ligand-2 (compound d) is a high affinity ligand targeting *FKBP12. FKBP12 ligand-2 can be used to selectively enhance the binding of heterobifunctional molecules to BRD4, enriching the drug intracellularly through the "CellTrap" effect to form a ternary complex of FKBP12-ligand-BRD4. This ternary complex has inhibitory activity against BRD4, thereby inhibiting the expression of BRD4 target genes (such as MYC) and inducing tumor cell death. FKBP*12 ligand-2 can be used for selective cancer research based on differences in intracellular presenter protein levels .

HY-170987

FKBP12 Ligand-Linker Conjugate 1	Target Protein Ligand-Linker Conjugates FKBP	Cancer
FKBP12 Ligand-Linker Conjugate 1 is the conjugate composed of a target protein ligand for *FKBP12* and a linker. FKBP12 Ligand-Linker Conjugate 1 can be used for synthesis of PROTAC degrader MC-25B (HY-170983) .

HY-170983

MC-25B	FKBP	Cancer
MC-25B is a specific *FKBP12* PROTAC degrader. MC-25B degrades *FKBP12* with a DC₅₀ of 0.35 μM and a D_max of 89%. MC-25B facilitates the degradation of nuclear-localized *FKBP12* through a DCAF16-dependent mechanism. (Pink: *FKBP12* ligand (HY-170988); Blue: E3 ligase ligand HY-170986); Black: linker (HY-128844); FKBP12 ligand+ linker (HY-170987)) .

HY-173082

10-SLF	PROTACs FKBP	Cancer
10-SLF is a PROTAC *FKBP12* degrader. 10-SLF induces a ternary complex between FKBP12 and FBXW7-R465C, and promotes FBXW7-R465C-dependent proteasomal degradation of FKBP12. 10-SLF selectively reduces FKBP12 levels in cells expressing FBXW7-R465C. Pink: FKBP12 ligand (HY-170988); Black: linker (HY-W004640); Blue: E3 ligase ligand .

HY-170988

FKBP12 ligand-1	FKBP Ligands for Target Protein for PROTAC	Cancer
FKBP12 ligand-1 is a targeting protein ligand of MC-25B (HY-170983), which is a specific *FKBP12* PROTAC .

HY-161794

SP3N	FKBP	Cancer
SP3N is a specific degrader of the prolyl isomerase (FKBP12). The alkylamine of SP3N is metabolized to a reactive aldehyde (SP3CHO), which recruits the SCF ^FBXO22 ligase for *FKBP12* degradation. SP3N may be used in research for cancer .

HY-145712

ElteN378	FKBP	Cancer
ElteN378 is an inhibitors of *FKBP12e*. ElteN378 can be used in study Alzheimer disease, Parkinson disease, Amyotrophic Lateral Sclerosis, proliferation disorders and cancer .

HY-10218S1

Everolimus-13C2,d4 RAD001-¹³C₂,d₄; SDZ-RAD-¹³C₂,d₄	Isotope-Labeled Compounds Bacterial Autophagy FKBP mTOR Apoptosis	Cancer
Everolimus- ¹³C₂,d₄ (RAD001- ¹³C₂,d₄) is ¹³C labeled Everolimus. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to *FKBP-12* to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

Cat. No.	Product Name	Type

HY-10219G

Rapamycin

Sirolimus; AY-22989; NSC 226080

Fluorescent Dyes

Rapamycin (Sirolimus) (GMP) is Rapamycin (HY-10219) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-10219GL

Rapamycin (GMP Like)

Sirolimus (GMP Like); AY-22989 (GMP Like); NSC 226080 (GMP Like)

Fluorescent Dyes

Rapamycin (Sirolimus) GMP Like is Rapamycin (HY-10219) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

Cat. No.	Product Name	Type

HY-10219G

Rapamycin

Sirolimus; AY-22989; NSC 226080

Biochemical Assay Reagents

HY-10219GL

Rapamycin (GMP Like)

Sirolimus (GMP Like); AY-22989 (GMP Like); NSC 226080 (GMP Like)

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-P4581

Suc-Ala-Leu-Pro-Phe-pNA Suc-ALPF-pNA	FKBP	Others
Suc-Ala-Leu-Pro-Phe-pNA (Suc-ALPF-pNA) is a synthetic polypeptide substrate that targets FK506-binding protein (FKBP). Suc-Ala-Leu-Pro-Phe-pNA can be used to determine peptidyl-prolyl cis-trans isomerase activity via the chymotrypsin-coupled assay. Suc-Ala-Leu-Pro-Phe-pNA serves as a substrate for human FK506-binding protein hFKBP-12 in the chymotrypsin-FKBP coupled PPIase assay. Suc-Ala-Leu-Pro-Phe-pNA is applicable for the detection and research of PPIase activity .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-10219

Rapamycin Maximum Cited Publications 1338 Publications Verification Sirolimus; AY-22989; NSC 226080	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Classification of Application Fields Antibiotics Anti-aging Disease Research Disease Research Fields Source Classification Cancer	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial
Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-13756

Tacrolimus 100+ Cited Publications FK506; Fujimycin; FR900506	Infection Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Animals Classification of Application Fields Antibiotics Disease Research Inflammation/Immunology Disease Research Fields Source Classification	Phosphatase FKBP Bacterial Autophagy Antibiotic
Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .

HY-13756A

Tacrolimus monohydrate 100+ Cited Publications FK506 monohydrate; Fujimycin monohydrate; FR900506 monohydrate	Infection Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Classification of Application Fields Antibiotics Disease Research Inflammation/Immunology Disease Research Fields Source Classification	Phosphatase FKBP Autophagy Bacterial Antibiotic
Tacrolimus monohydrate (FK506 monohydrate), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex and inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .

HY-10219R

Rapamycin (Standard) Sirolimus (Standard); AY-22989 (Standard); NSC 226080 (Standard)	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Antibiotics Disease Research Endogenous metabolite Source Classification	Reference Standards mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial
Rapamycin (Standard) is the analytical standard of Rapamycin (HY-10219). This product is intended for research and analytical applications. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-B0652

Etonogestrel 3-Oxodesogestrel; 3-keto-Desogestrel	Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Steroids Source Classification	Drug Metabolite Estrogen Receptor/ERR Progesterone Receptor Endogenous Metabolite FKBP
Etonogestrel (3-Oxodesogestrel), a biologically active metabolite of progestin Desogestrel, binds with high affinity to progesterone receptors and estrogen receptors in the target organs . Etonogestrel induce *FKBP51* mRNA and protein expression in cultured human endometrial stromal cells (HESCs) .

HY-13756R

Tacrolimus (Standard) FK506 (Standard); Fujimycin (Standard); FR900506 (Standard)	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Animals Antibiotics Disease Research Source Classification	Reference Standards Phosphatase FKBP Bacterial Autophagy Antibiotic
Tacrolimus (Standard) is the analytical standard of Tacrolimus. This product is intended for research and analytical applications. Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .

HY-B0652R

Etonogestrel (Standard) 3-Oxodesogestrel (Standard); 3-keto-Desogestrel (Standard)	Structural Classification Endogenous metabolite Steroids Source Classification	Drug Metabolite Reference Standards Estrogen Receptor/ERR Progesterone Receptor Endogenous Metabolite FKBP
Etonogestrel (Standard) is the analytical standard of Etonogestrel. This product is intended for research and analytical applications. Etonogestrel (3-Oxodesogestrel), a biologically active metabolite of progestin Desogestrel, binds with high affinity to progesterone receptors and estrogen receptors in the target organs . Etonogestrel induce FKBP51 mRNA and protein expression in cultured human endometrial stromal cells (HESCs) .

Cat. No.	Product Name	Chemical Structure

HY-13756S

Tacrolimus-13C,d2 1 Publications Verification
Tacrolimus- ¹³C,d₂ is a ¹³C-labeled and deuterium labeled Tacrolimus. Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .

HY-10218S

Everolimus-d4
Everolimus-d₄ is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

HY-10219S

Rapamycin-d3 1 Publications Verification
Rapamycin-d₃ is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .

HY-10219S1

Rapamycin-13C,d3
Rapamycin- ¹³C,d₃ (Sirolimus- ¹³C,d₃) is the ¹³C and deuterium labeled Rapamycin (HY-10219) . Rapamycin is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .

HY-13756S2

Tacrolimus-d3
Tacrolimus-d₃ (FK506-d₃) is deuterium labeled Tacrolimus. Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .

HY-10218S1

Everolimus-13C2,d4

Everolimus- ¹³C₂,d₄ (RAD001- ¹³C₂,d₄) is ¹³C labeled Everolimus. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

HY-B0652S1

Etonogestrel-d6
Etonogestrel-d₆ is deuterium labeled Etonogestrel. Etonogestrel (3-Oxodesogestrel), a biologically active metabolite of progestin Desogestrel, binds with high affinity to progesterone receptors and estrogen receptors in the target organs . Etonogestrel induce FKBP51 mRNA and protein expression in cultured human endometrial stromal cells (HESCs) .

HY-W765245

Rapamycin-13C,d3-1
Rapamycin- ¹³C,d₃-1 (Sirolimus- ¹³C,d₃-1) is the deuterium labeled and ¹³C-labeled Rapamycin (HY-10219). Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-16046S

Rimiducid-d4
Rimiducid-d₄ (AP1903-d₄) is the deuterium labeled Rimiducid (HY-16046). Rimiducid (AP1903) is a dimerizer agent that acts by cross-linking the FKBP domains. Rimiducid (AP1903) dimerizes the Caspase 9 suicide switch and rapidly induces apoptosis.

Cat. No.	Product Name		Classification

HY-176502

FKBP12 ligand-3		Alkynes
FKBP12 ligand-3 (compound dj) is a high-affinity ligand targeting *FKBP12. FKBP12 ligand-3 can be used to selectively enhance the binding of heterobifunctional molecules to BRD4, enriching the drug intracellularly through the "CellTrap" effect to form a ternary complex of FKBP12-ligand-BRD4. This ternary complex has inhibitory activity against BRD4, thereby inhibiting the expression of BRD4 target genes (such as MYC) and inducing tumor cell death. FKBP*12 ligand-3 can be used for selective cancer research based on differences in intracellular presenter protein levels .

HY-176501

FKBP12 ligand-2		Alkynes
FKBP12 ligand-2 (compound d) is a high affinity ligand targeting *FKBP12. FKBP12 ligand-2 can be used to selectively enhance the binding of heterobifunctional molecules to BRD4, enriching the drug intracellularly through the "CellTrap" effect to form a ternary complex of FKBP12-ligand-BRD4. This ternary complex has inhibitory activity against BRD4, thereby inhibiting the expression of BRD4 target genes (such as MYC) and inducing tumor cell death. FKBP*12 ligand-2 can be used for selective cancer research based on differences in intracellular presenter protein levels .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10219G

Rapamycin Sirolimus; AY-22989; NSC 226080	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial	Infection Cancer
Rapamycin (Sirolimus) (GMP) is Rapamycin (HY-10219) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

FKBPs

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Oligonucleotides

GMP Molecules

Natural
Products